At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 May 1995 Discontinued-I for Cancer in United Kingdom (Unknown route)
- 18 May 1995 Discontinued-I for Cancer in USA (Unknown route)